Matthew Ronsheim
Corporate Officer/Principal chez ENTASIS THERAPEUTICS HOLDINGS INC.
Fortune : 639 653 $ au 31/05/2024
Postes actifs de Matthew Ronsheim
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01/09/2020 | - |
Historique de carrière de Matthew Ronsheim
Anciens postes connus de Matthew Ronsheim
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/06/2016 | 01/08/2019 |
| Corporate Officer/Principal | 01/06/2016 | 01/08/2019 |
Formation de Matthew Ronsheim
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Bourse
- Insiders
- Matthew Ronsheim
- Expérience
